Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and...
-
date post
20-Dec-2015 -
Category
Documents
-
view
217 -
download
0
Transcript of Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and...
![Page 1: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/1.jpg)
Introduction to Health Economics
Nelly BIONDI ,
South African Centre of Epidemiological Modelling and Analysis (SACEMA),
Makerere University, 21th July 2009
![Page 2: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/2.jpg)
Outline
• What is Health Economics?
• Generic steps in Economic evaluation.
• Types of economic evaluation.
2
![Page 3: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/3.jpg)
Part 1:
What is Health Economics?The importance of Economic evaluation.
![Page 4: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/4.jpg)
4
Economists view of the world…
Pessimist: bottle ½ empty Optimist: bottle ½ full Economist: bottle ½ WASTED!!
![Page 5: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/5.jpg)
5
The ‘Health Economic’ problem
Unlimited healthcare “wants” with rapid growth in health expenditure.
Insufficient health sector resources.
Choosing between ‘wants’ we can ‘afford’ given our resource ‘budget’.
![Page 6: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/6.jpg)
6
Concept of opportunity cost
• “ The value of forgone benefit which could be obtained from a resource in its next-best alternative use”.
• The aim is to choose activities where benefits outweigh opportunity cost.
Pg ‘B’Pg ‘A’
Budget
![Page 7: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/7.jpg)
7
What is Health Economics?
Theoretical framework to help healthcare professionals ,decision-makers or governments to make choices on…
…HOW to maximize the health of population given constrained health producing resources.
What health economists need is… To understand the relationship between resources used and
health outcomes achieved by alternative options. …and compare!
![Page 8: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/8.jpg)
8
Economic evaluation is…
“ The comparative analysis of alternative courses of action in terms of both their costs and consequences in order to assist policy decisions” (Drummond et al,1997)
Economic evaluation is not “choosing the cheapest”.
![Page 9: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/9.jpg)
9
Economic Evaluation criteria
Economic evaluation is used to ensure that limited resources are allocated as efficiently as possible. Technical efficiency: meeting a given objective at least cost. Allocative efficiency: producing exactly what society wants.
Society may have other goals when allocating resources: equity or ethical issues. Horizontal equity: ‘equal treatment of equals’. Vertical equity: ‘unequal treatment of unequals’.
![Page 10: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/10.jpg)
Part 2:
Generic steps in Economic Evaluation
![Page 11: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/11.jpg)
11
Stages in economic evaluation
![Page 12: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/12.jpg)
12
Deciding upon the study question
Identifying the problem and aims of evaluation What is the problem? Why is this problem important? What aspects of the problem need to be explained?
Choosing the alternative options Describing the interventions accurately. Defining the counterfactual intervention (comparator).
Defining the audience Defining the info needs of the audience. Considering how the audience will use the study results.
![Page 13: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/13.jpg)
13
Deciding upon the study question
Defining the perspective of the study Patient / Providers / Payers / Healthcare system / Society. Choosing a perspective depends on the audience.
Defining the time frame and analytic horizon Analytic horizon > Time frame.
Choosing the study format Prospective / Retrospective / Model. Depends on data, time and resources available.
![Page 14: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/14.jpg)
14
Assessment of costs
Overview of costing process:
Identification of costs Cost type: direct vs indirect vs intangible. Cost category: programme, patient. Organizational level: national, regional, district. Input category: capital vs recurrent. Intervention activities: planning, administration, media, training. Time: start-up vs post-implementation. Funding: national govt vs NGO vs donor.
![Page 15: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/15.jpg)
15
Assessment of costs
Measurement Measure in natural physical units (e.g. hours of labour time). Fixed, variable and total costs. Average versus marginal costs. Marginal versus incremental costs.
![Page 16: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/16.jpg)
16
Assessment of costs
(For a population of 10,000, costs include stool tests and barium-enema examinations on those found positive)
From Neuhauser and Lewicki (1975)
2,451176,33171.94206
2,268163,14171.94175
2,059148,11671.93854
1,811130,19971.90033
1,507107,69071.44242
1,17577,51165.94961
Average cost per case detected (£)
Total costs(£)
Total cases detected
Number of tests
Table 1: Number of cases detected & costs of screening with sequential guaiac tests
(For a population of 10,000, costs include stool tests and barium-enema examinations on those found positive)
From Neuhauser and Lewicki (1975)
2,451176,33171.94206
2,268163,14171.94175
2,059148,11671.93854
1,811130,19971.90033
1,507107,69071.44242
1,17577,51165.94961
Average cost per case detected (£)
Total costs(£)
Total cases detected
Number of tests
Table 1: Number of cases detected & costs of screening with sequential guaiac tests
47,107,21413,1900.00036
4,724,69515,0240.00325
469,53417,9170.03824
49,15022,5090.45803
5,49230,1795.49562
1,17577,51165.94961
Marginal cost (additional cost per
additional case detected (£)
Additional costs(£)
Additional cases detected
Number of tests
Table 2: Changes in cases detected and in costs of sequential guaiactests
47,107,21413,1900.00036
4,724,69515,0240.00325
469,53417,9170.03824
49,15022,5090.45803
5,49230,1795.49562
1,17577,51165.94961
Marginal cost (additional cost per
additional case detected (£)
Additional costs(£)
Additional cases detected
Number of tests
Table 2: Changes in cases detected and in costs of sequential guaiactests
![Page 17: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/17.jpg)
17
Assessment of costs
Valuation Market prices (e.g. wage rates) used unless strong belief they do
not reflect opportunity cost (e.g. volunteers). Local currencies vs international currencie. Adjustments for price inflation.
Calculation Multiply unit of measurement by unit cost (e.g. 2 hours of time at
$5 per hour = $10 labour cost).
![Page 18: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/18.jpg)
18
Assessment of health effects
Overview of the process:
Identification Which outcome measure is employed depends on the objective of
the evaluation. This then determines the type of evaluation.
Measurement Measure effectiveness not efficacy. Measure (count) in natural physical units. Measure final not intermediate outcomes.
![Page 19: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/19.jpg)
Assessment of health effects
Valuation if appropriate Value is determined by benefits sacrificed elsewhere (see
opportunity cost again). Valuation either in terms of:
Utility (e.g. QALY, DALY, HYE) Money (e.g. WTP)
19
![Page 20: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/20.jpg)
20
Assessment of health effects
Zoom on the concept of QALY:
![Page 21: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/21.jpg)
21
Adjusting for timing
Discounting Prefer to have benefits now and bear costs in the future – ‘time
preference’ Rate of time preference is termed ‘discount rate To allow for differential timing of costs (and benefits) between
programmes all future costs (and benefits) should be stated in terms of their present value using discount rate.
Thus, future costs given less weight than present costs.
Annuitization of capital costs Capital costs represent an investment at start-up in an asset
which is used and depreciated over time. Annualise the initial capital outlay over the useful life of asset.
![Page 22: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/22.jpg)
22
Sensitivity analysis
Process of assessing the robustness of an economic evaluation by considering the effects of uncertainty.
Consists in: Identifying the (uncertain) variables. Specifying the plausible range over which they should vary. Recalculating results, usually based on:
One-way analysis Multi-way analysis Extreme scenario analysis Threshold analysis.
![Page 23: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/23.jpg)
Part 3:
Types of Economic Evaluation
![Page 24: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/24.jpg)
24
Basic types of economic evaluation
Cost minimization Analysis (CMA) Cost-effectiveness Analysis (CEA) Cost-utility Analysis (CUA) Cost-benefit Analysis (CBA)
![Page 25: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/25.jpg)
25
Cost minimization Analysis
Specific type of analysis in which the outcomes of the 2 (or more) healthcare interventions are assumed equal.
Therefore economic evaluation is based solely on comparative costs.
Result: least cost alternative.
![Page 26: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/26.jpg)
26
Cost-effectiveness Analysis
In CEA, outcomes are measured in natural or physical units (e.g. heart attacks avoided, deaths avoided…).
Only one domain of outcomes can be explored at a time.
Result: cost per unit of consequence (e.g. cost/LY gained)
![Page 27: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/27.jpg)
27
Cost-effectiveness Analysis
Decision rule:Two programmes A (comparator) and B.– If Outcome B = Outcome A => Compare costs (CMA).– If Outcome B > Outcome A and Cost B < Cost A, B is dominant.– If Outcome B > Outcome A and Cost B > Cost A, we have to
make a decision.
In order to make a decision on which intervention to choose, a cost-effectiveness ratio (CER) should be calculated.
![Page 28: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/28.jpg)
28
Cost-effectiveness Analysis
The most commonly CERs used are the: Average cost-effectiveness ratio (ACER)
Incremental cost-effectiveness ratio (ICER)
The next question is : Is the intervention “cost-effective”?
ICER=Cost B−Cost A
Effectiveness B−Effectiveness A
ACER=Cost B
Effectiveness B
![Page 29: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/29.jpg)
29
Cost-effectiveness Analysis
There is no ‘magic’ cut-off number that establishes whether or not an intervention is ‘cost-effective’.
It will depend on what is termed the decision maker’s ‘ceiling ratio’.
The ceiling ratio can be inferred from the amount that decision-makers are willing to pay.
To make a decision: If ICER of the program ≤ ceiling ratio → adopt the program If ICER of the program > ceiling ratio → do not adopt the
program
![Page 30: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/30.jpg)
30
Cost-effectiveness Analysis
The cost-effectiveness acceptability Plane:
![Page 31: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/31.jpg)
31
Cost-utility Analysis
In CUA, the outcomes are measured in healthy years, to which a value has been attached.
CUA is multidimensional and incorporates considerations of quality of life as well as quantity of life using a common unit.
Result: Cost per unit of consequence (e.g. cost/QALY).
![Page 32: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/32.jpg)
32
Cost-benefit Analysis
CBA try to value the outcomes in monetary terms, so as to make them commensurate with the costs.
Result: Net benefit or cost-benefit ratio.
CBAs rarely used in health care.
![Page 33: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/33.jpg)
33
Summary
Type of Analysis ResultResultConsequencesCosts
Cost Minimisation
Cost BenefitCost Benefit
Cost Utility
Cost Effectiveness
Money
Single or multiple effects not necessarily common.
Valued as “utility” eg. QALY
Different magnitude of a common measure eg.,
LY’s gained, blood pressure reduction.
Least cost alternative.Least cost alternative.Identical in all
respects.
MoneyMoney
Money
MoneyCost per unit of
consequence eg. cost per LY gained.
Cost per unit of consequence eg. cost
per LY gained.
Cost per unit of consequence eg. cost
per QALY.
Cost per unit of consequence eg. cost
per QALY.
As for CUA but valued in money.As for CUA but
valued in money.Net £
cost: benefit ratio.Net £
cost: benefit ratio.
![Page 34: Introduction to Health Economics Nelly BIONDI, South African Centre of Epidemiological Modelling and Analysis (SACEMA), Makerere University, 21th July.](https://reader030.fdocuments.us/reader030/viewer/2022032704/56649d535503460f94a2edcb/html5/thumbnails/34.jpg)
Thank you…! Merci!...Weebale!R. Baltussen, K. Floyd and C. Dye, (2005) “Cost effectiveness analysis of strategies for tuberculosis control in developing countries,” British Medical Journal, 331;1364, (originally published online 10 Nov 2005; doi:10.1136/bmj.38645.660093.68)
D. R. Hogan, R. Baltussen, C. Hayashi, J. A. Lauer, J. A. Salomon, (2005) “Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries,” British Medical Journal, doi:10.1136/bmj.38643.368692.68 (published 10 November 2005)
C. A. Goodman, P. G. Coleman, A. J. Mills, (1999) “Cost-effectiveness of malaria control in sub-Saharan Africa” The Lancet, vol. 354, 378-85, July.
mailto: [email protected]